Evidence map›Paper›PMID 37172726›Full record

ArticleThe Journal of biological chemistry2023

Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor.

Andrea Piserchio, Eta A Isiorho, Kevin N Dalby, Ranajeet Ghose

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Andrea PiserchioDepartment of Chemistry and Biochemistry, The City College of New York, New York, New York, USA.
Eta A IsiorhoMacromolecular Crystallization Facility, CUNY ASRC, New York, New York, USA.
Kevin N DalbyDivision of Chemical Biology and Medicinal Chemistry, The University of Texas, Austin, Texas, USA; Interdisciplinary Life Sciences Graduate Program, The University of Texas, Austin, Texas, USA. Electronic address: dalby@austin.utexas.edu.
Ranajeet GhoseDepartment of Chemistry and Biochemistry, The City College of New York, New York, New York, USA; PhD Program in Biochemistry, The Graduate Center of CUNY, New York, New York, USA; PhD Program in Chemistry, The Graduate Center of CUNY, New York, New York, USA; PhD Program in Physics, The Graduate Center of CUNY, New York, New York, USA. Electronic address: rghose@ccny.cuny.edu.
The Graduate Center, CUNY · USCity College of New York · USThe University of Texas at Austin · US

Funding

Regulation of eEF-2K an Energy and Nutrient SensorR01GM123252 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI DALBY, KEVIN N, GHOSE, RANAJEET · 2017 to 2024
$2.7M
NIGMS NIH HHS R01 GM123252
6 · The paper itself

Abstract

The calmodulin-activated α-kinase, eukaryotic elongation factor 2 kinase (eEF-2K), serves as a master regulator of translational elongation by specifically phosphorylating and reducing the ribosome affinity of the guanosine triphosphatase, eukaryotic elongation factor 2 (eEF-2). Given its critical role in a fundamental cellular process, dysregulation of eEF-2K has been implicated in several human diseases, including those of the cardiovascular system, chronic neuropathies, and many cancers, making it a critical pharmacological target. In the absence of high-resolution structural information, high-throughput screening efforts have yielded small-molecule candidates that show promise as eEF-2K antagonists. Principal among these is the ATP-competitive pyrido-pyrimidinedione inhibitor, A-484954, which shows high specificity toward eEF-2K relative to a panel of "typical" protein kinases. A-484954 has been shown to have some degree of efficacy in animal models of several disease states. It has also been widely deployed as a reagent in eEF-2K-specific biochemical and cell-biological studies. However, given the absence of structural information, the precise mechanism of the A-484954-mediated inhibition of eEF-2K has remained obscure. Leveraging our identification of the calmodulin-activatable catalytic core of eEF-2K, and our recent determination of its long-elusive structure, here we present the structural basis for its specific inhibition by A-484954. This structure, which represents the first for an inhibitor-bound catalytic domain of a member of the α-kinase family, enables rationalization of the existing structure-activity relationship data for A-484954 variants and lays the groundwork for further optimization of this scaffold to attain enhanced specificity/potency against eEF-2K.

Indexed as

Adenosine TriphosphateCalmodulinElongation Factor 2 KinaseAnimalsCatalytic DomainHumansPeptide Chain Elongation, TranslationalPeptide Elongation Factor 2PhosphorylationPyridinesPyrimidinesStructure-Activity RelationshipA-484954Adenosine TriphosphateCalmodulinEEF2K protein, humanElongation Factor 2 KinasePeptide Elongation Factor 2PyridinesPyrimidinesalpha-kinaseATP-competitive kinase inhibitoratypical kinasecalmodulin-dependent kinaseeukaryotic elongation factor 2 kinaseprotein translation

Identifiers

PMID37172726
PMCPMC10318512
OpenAlexW4376598171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.